FDA Approved: ZERBAXA — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for ZERBAXA (ceftolozane and tazobactam) from Merck, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Intra-abdominal Infection
• Complicated Urinary Tract Infection
• Hospital-acquired Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Zerbaxa (ceftolozane-tazobactam)

Snippet

SUPPL AP for ZERBAXA (CEFTOLOZANE AND TAZOBACTAM)